Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based medicines for hematologic and inflammatory diseases. The company uses a proprietary platform to design constrained peptides that modulate validated biological targets.
Its lead wholly owned program is rusfertide (PTG-300), a hepcidin mimetic in late-stage development for polycythemia vera and other disorders of iron regulation. Protagonist also collaborates with Janssen on oral interleukin-23 receptor antagonists, including JNJ-2113 (formerly PN-235) for immune-mediated conditions. Additional pipeline candidates target gastrointestinal and systemic inflammatory pathways.
Protagonist is headquartered in the United States and conducts research and development across the U.S. and Australia.
